05/12/2025 Important insight for Castleman disease patients: Individuals diagnosed with Castleman disease (CD) and TAFRO syndrome display a wide range of clinical symptoms. Some patients may present with both CD and TAFRO syndrome concurrently. This retrospective study conducted across multiple centers in Japan examined 321 cases to determine if the quantity and position of swollen lymph nodes could forecast the clinical progression and intensity of these conditions. The study revealed that patients with TAFRO syndrome exhibited lymphadenopathy across all ranges of lymph node region counts. No specific clinical patterns were associated with the number of affected lymph node regions in CD patients, regardless of whether they also had TAFRO syndrome. The results suggest a comprehensive clinical evaluation, rather than relying solely on lymph node count, is crucial for effectively managing these conditions.
Summary: This open-access research article reports a retrospective, multicenter study of 321 Japanese patients with Castleman disease (CD) and/or TAFRO syndrome—the latter characterized by thrombocytopenia, anasarca, fever, bone-marrow (reticulin) fibrosis, and organomegaly—undertaken to test whether the number and location of enlarged lymph nodes can predict how these conditions progress and how severe they become. Both CD and TAFRO produce a wide range of manifestations, including varying patterns of lymphadenopathy, systemic inflammation, and organ dysfunction, and the two can occur concurrently in the same patient. The investigators found that patients with TAFRO syndrome showed lymphadenopathy across the full spectrum of lymph-node region counts, and that no specific clinical patterns tracked with the number of affected regions in CD patients—whether or not they also had TAFRO. The authors conclude that lymph-node count alone is not a reliable guide to disease behavior, and that comprehensive clinical evaluation is essential for effective management. They note that further studies are needed to establish dependable diagnostic markers and to predict disease severity at diagnosis, with the goal of improving patient outcomes.